Avatrombopag

Drug Profile

Avatrombopag

Alternative Names: AKR-501; AKR-501 monomaleate; AVA; Avatrombopag maleate; E-5501; YM-477

Latest Information Update: 23 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Astellas Pharma
  • Developer Dova Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic thrombocytopenic purpura; Thrombocytopenia

Most Recent Events

  • 10 Aug 2017 Dova announces intention to submit NDA to US FDA for Thrombocytopenia in Q3 2017
  • 10 Aug 2017 Dovo Pharmaceuticals intends to launch avatrombopag in USA in 2018
  • 06 Jan 2017 Dova Pharmaceuticals completes a phase III trial for Thrombocytopenia in USA, Canada, Japan, Australia, Argentina, Brazil, China, Mexico, Israel, France, Italy, the Czech Republic, Belgium, Germany, Spain, Romania and Russia (PO) (NCT01976104)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top